|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM262053721 |
| 003 |
DE-627 |
| 005 |
20231224200922.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.06.014
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0873.xml
|
| 035 |
|
|
|a (DE-627)NLM262053721
|
| 035 |
|
|
|a (NLM)27377533
|
| 035 |
|
|
|a (PII)S1521-6616(16)30136-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Klaver, Yarne
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2017
|
| 500 |
|
|
|a Date Revised 13.08.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016. Published by Elsevier Inc.
|
| 520 |
|
|
|a Autologous T-cells genetically modified to express a chimeric antigen receptor (CAR) against carboxy-anhydrase-IX (CAIX) were administered to twelve patients with CAIX-positive metastatic renal cell carcinoma. Here, we questioned whether plasma cytokine levels following treatment or in vitro cytokine production from the T-cell infusion products could serve as predictors for peripheral T-cell persistence or in vivo T-cell activity. We demonstrated that CAR surface as well as gene expression are down-regulated following T-cell infusion, and that peripheral numbers of CAR T-cells are best captured by flow cytometry and not by qPCR. Numbers of CAR T-cells in blood correlated with plasma levels of IFN-γ and IL-6, but not with any of the other cytokines tested. Plasma IFN-γ or IL-6 levels did not correlate with liver enzyme values. Thus, out of 27 cytokines tested, IFN-γ and IL-6 levels in plasma are potential surrogate markers for CAR T-cell persistence in solid tumors
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Chimeric antigen receptor
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a IFN-γ
|
| 650 |
|
4 |
|a Immune monitoring
|
| 650 |
|
4 |
|a Renal cell cancer
|
| 650 |
|
4 |
|a T-cell
|
| 650 |
|
7 |
|a Biomarkers, Tumor
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-6
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a van Steenbergen, Sabine C L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sleijfer, Stefan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Debets, Reno
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lamers, Cor H J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 169(2016) vom: 05. Aug., Seite 107-113
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:169
|g year:2016
|g day:05
|g month:08
|g pages:107-113
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.06.014
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 169
|j 2016
|b 05
|c 08
|h 107-113
|